Zions Bancorporation N.A. Sells 55 Shares of Danaher Co. (NYSE:DHR)

Zions Bancorporation N.A. reduced its stake in shares of Danaher Co. (NYSE:DHR) by 3.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,793 shares of the conglomerate’s stock after selling 55 shares during the quarter. Zions Bancorporation N.A.’s holdings in Danaher were worth $412,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. TIAA Trust National Association grew its stake in Danaher by 28.3% in the 4th quarter. TIAA Trust National Association now owns 101,121 shares of the conglomerate’s stock worth $23,212,000 after acquiring an additional 22,326 shares in the last quarter. Ashton Thomas Securities LLC increased its holdings in Danaher by 8.0% during the 4th quarter. Ashton Thomas Securities LLC now owns 864 shares of the conglomerate’s stock worth $202,000 after purchasing an additional 64 shares during the period. Modern Wealth Management LLC raised its position in Danaher by 30.5% during the 4th quarter. Modern Wealth Management LLC now owns 1,087 shares of the conglomerate’s stock valued at $250,000 after purchasing an additional 254 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in shares of Danaher in the 4th quarter worth $692,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd grew its position in shares of Danaher by 52.9% during the 4th quarter. Napean Trading & Investment Co Singapore PTE Ltd now owns 55,497 shares of the conglomerate’s stock worth $12,739,000 after buying an additional 19,193 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock opened at $210.15 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business has a fifty day moving average of $215.86 and a 200 day moving average of $237.56. The firm has a market capitalization of $150.19 billion, a price-to-earnings ratio of 39.80, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the business earned $2.09 earnings per share. As a group, research analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is presently 24.24%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Raymond James restated a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Barclays lowered their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.